Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Relationship between UGT1A1*27 and UGT1A1*7 polymorphisms and irinotecan-related toxicities in patients with lung cancer.

Fukuda M, Okumura M, Iwakiri T, Arimori K, Honda T, Kobayashi K, Senju H, Takemoto S, Ikeda T, Yamaguchi H, Nakatomi K, Matsuo N, Mukae H, Ashizawa K.

Thorac Cancer. 2018 Jan;9(1):51-58. doi: 10.1111/1759-7714.12535. Epub 2017 Oct 20.

2.

Development of the Virtual Physical Assessment Learning Material That Allows the Learners to Check Drug Efficacy and Early Detection of Adverse Effects through Virtual Experience.

Tokunaga J, Takamura N, Kourogi Y, Imada M, Kozasa A, Komori K, Ono C, Nishimura A, Ogata K, Setoguchi N, Matsuoka T, Kai M, Sato K, Arimori K.

Yakugaku Zasshi. 2016;136(10):1439-1444.

3.

An advanced objective structured clinical examination using patient simulators to evaluate pharmacy students' skills in physical assessment.

Tokunaga J, Takamura N, Ogata K, Setoguchi N, Utsumi M, Kourogi Y, Osaki T, Ozaki M, Sato K, Arimori K.

Am J Pharm Educ. 2014 Dec 15;78(10):184. doi: 10.5688/ajpe7810184.

4.

Pramipexole reduces parkinsonian tremor induced by pilocarpine infusion in the rat striatum.

Yasuda K, Abe H, Koganemaru G, Ikeda T, Arimori K, Ishida Y.

Pharmacol Biochem Behav. 2015 Apr;131:1-5. doi: 10.1016/j.pbb.2015.01.012. Epub 2015 Jan 24.

PMID:
25622778
5.

Albumin-binding of diclofenac and the effect of a site II inhibitor in the aqueous humor of cataract patients with the instillation of diclofenac.

Osaki T, Ozaki M, Takamura N, Ogata K, Tokunaga J, Setoguchi N, Arimori K.

Biopharm Drug Dispos. 2014 May;35(4):218-27. doi: 10.1002/bdd.1887. Epub 2014 Feb 12.

PMID:
24395676
6.

A diclofenac suppository-nabumetone combination therapy for arthritic pain relief and a monitoring method for the diclofenac binding capacity of HSA site II in rheumatoid arthritis.

Setoguchi N, Takamura N, Fujita K, Ogata K, Tokunaga J, Nishio T, Chosa E, Arimori K, Kawai K, Yamamoto R.

Biopharm Drug Dispos. 2013 Mar;34(2):125-36. doi: 10.1002/bdd.1829. Epub 2013 Jan 24.

PMID:
23225308
7.

Caffeine increases the antitumor effect of Cisplatin in human hepatocellular carcinoma cells.

Kawano Y, Nagata M, Kohno T, Ichimiya A, Iwakiri T, Okumura M, Arimori K.

Biol Pharm Bull. 2012;35(3):400-7.

8.

Hyuganatsu orange (Citrus tamurana Hort. Ex Tanaka) contains a water soluble substance that suppresses bone loss in ovariectomized rats.

Yamaguchi M, Sameshima H, Ikenoue T, Tsuboi M, Hidaka M, Arimori K.

Biosci Biotechnol Biochem. 2012;76(2):364-7. Epub 2012 Feb 7.

9.

Hepatocyte growth factor suppresses the anticancer effect of irinotecan by decreasing the level of active metabolite in HepG2 cells.

Okumura M, Iwakiri T, Takagi A, Hirabara Y, Kawano Y, Arimori K.

Biochem Pharmacol. 2011 Dec 1;82(11):1720-30. doi: 10.1016/j.bcp.2011.07.095. Epub 2011 Aug 5.

PMID:
21840303
10.

Hepatic fibrosis does not affect the pharmacokinetics of 5-fluorouracil in rats.

Nagata M, Hidaka Y, Hatakeyama K, Kawano Y, Iwakiri T, Okumura M, Arimori K.

Biopharm Drug Dispos. 2011 Mar;32(2):126-30. doi: 10.1002/bdd.744. Epub 2010 Dec 28.

PMID:
21341281
11.

Effect of acute hepatic failure on the hepatic first-pass effect of 5-fluorouracil in rats.

Nagata M, Hidaka Y, Hidaka M, Kawano Y, Iwakiri T, Okumura M, Arimori K.

J Pharm Pharmacol. 2010 May;62(5):598-603. doi: 10.1211/jpp/62.05.0006.

PMID:
20609061
12.

Safety, efficacy and pharmacokinetics of S-1 in a hemodialysis patient with advanced gastric cancer.

Tomiyama N, Hidaka M, Hidaka H, Kawano Y, Hanada N, Kawaguchi H, Arimori K, Nakamura C.

Cancer Chemother Pharmacol. 2010 Mar;65(4):807-9. doi: 10.1007/s00280-009-1216-1.

PMID:
20037758
13.

[Medical emergency education using emergency care simulators in the School of Pharmaceutical Sciences].

Tokunaga J, Takamura N, Ogata K, Yoshida H, Totoribe K, Nagata M, Hidaka M, Matsuoka T, Ono S, Yamamoto R, Arimori K.

Yakugaku Zasshi. 2008 Jul;128(7):1045-55. Japanese.

14.

Analysis of CYP3A inhibitory components of star fruit (Averrhoa carambola L.) using liquid chromatography-mass spectrometry.

Hosoi S, Shimizu E, Arimori K, Okumura M, Hidaka M, Yamada M, Sakushima A.

J Nat Med. 2008 Jul;62(3):345-8. doi: 10.1007/s11418-008-0239-y. Epub 2008 Mar 25.

PMID:
18404300
15.

Effect of acute hepatic failure on epirubicin pharmacokinetics after intrahepatic arterial injection in rats.

Nagata M, Matsuo Y, Hidaka M, Kawano Y, Okumura M, Tokunaga J, Takamura N, Arimori K.

Biol Pharm Bull. 2008 Mar;31(3):493-6.

16.

Inhibitory effects of fruit juices on cytochrome P450 2C9 activity in vitro.

Hidaka M, Nagata M, Kawano Y, Sekiya H, Kai H, Yamasaki K, Okumura M, Arimori K.

Biosci Biotechnol Biochem. 2008 Feb;72(2):406-11. Epub 2008 Feb 7.

17.

Dosage plan of a flurbiprofen injection product using inhibition of protein binding by lipid emulsion in rats.

Ogata K, Takamura N, Tokunaga J, Kawai K, Arimori K, Higuchi S.

J Pharm Pharmacol. 2008 Jan;60(1):15-20.

PMID:
18088500
18.

Hepatocyte growth factor increases uptake of estradiol 17beta-D-glucuronide and Oatp1 protein level in rat hepatocytes.

Iwakiri T, Okumura M, Matsunaga N, Ichihara E, Shiotsuki S, Nagata M, Kumagai Y, Kai H, Arimori K.

Eur J Pharmacol. 2008 Feb 2;580(1-2):19-26. Epub 2007 Oct 25.

PMID:
18031729
19.

[Need for pharmaceutical skill in using displacement of protein binding].

Takamura N, Tokunaga J, Chosa E, Kawai K, Fujita K, Arimori K.

Yakugaku Zasshi. 2007 Nov;127(11):1805-11. Review. Japanese.

20.

Inhibition of carrier-mediated uptake of epirubicin reduces cytotoxicity in primary culture of rat hepatocytes.

Iwakiri T, Okumura M, Hidaka M, Kumagai Y, Ichihara E, Kawano Y, Arimori K.

J Appl Toxicol. 2008 Apr;28(3):329-36.

PMID:
17604344
21.

[Interpretations of laboratory test data on serum protein binding].

Takamura N, Tokunaga J, Arimori K.

Yakugaku Zasshi. 2007 Feb;127(2):231-6. Review. Japanese.

22.

Effects of pomegranate juice on human cytochrome P450 2C9 and tolbutamide pharmacokinetics in rats.

Nagata M, Hidaka M, Sekiya H, Kawano Y, Yamasaki K, Okumura M, Arimori K.

Drug Metab Dispos. 2007 Feb;35(2):302-5. Epub 2006 Nov 28.

PMID:
17132763
23.

Isolation of cytochrome P450 3A (CYP3A) inhibitors from Hyuganatsu, Citrus tamurana Hort.

Hosoi S, Shimizu E, Usami N, Yamamoto I, Arimori K, Okumura M, Hidaka M, Yamada M, Sakushima A.

J Nat Med. 2006 Jul;60(3):240-242. doi: 10.1007/s11418-006-0031-9. Epub 2006 Apr 14.

PMID:
29435884
24.

Adsorption of irinotecan onto oral adsorbent AST-120 (Kremezin) for preventing delayed diarrhea.

Hidaka M, Yamasaki K, Okumura M, Ogikubo T, Iwakiri T, Setoguchi N, Nishida K, Nagai K, Ikenoue T, Arimori K.

Cancer Chemother Pharmacol. 2007 Feb;59(3):321-8. Epub 2006 Jun 13.

PMID:
16770581
25.

Transient inhibition of cyp3a in rats by star fruit juice.

Hidaka M, Okumura M, Ogikubo T, Kai H, Fujita K, Iwakiri T, Yamasaki K, Setoguchi N, Matsunaga N, Arimori K.

Drug Metab Dispos. 2006 Mar;34(3):343-5. Epub 2005 Dec 2.

PMID:
16326816
26.

Inhibitory effects of amino-acid fluids on drug binding to site II of human serum albumin in vitro.

Yamasaki K, Kuga N, Takamura N, Furuya Y, Hidaka M, Iwakiri T, Nishii R, Okumura M, Kodama H, Kawai K, Arimori K.

Biol Pharm Bull. 2005 Mar;28(3):549-52.

27.

Effects of pomegranate juice on human cytochrome p450 3A (CYP3A) and carbamazepine pharmacokinetics in rats.

Hidaka M, Okumura M, Fujita K, Ogikubo T, Yamasaki K, Iwakiri T, Setoguchi N, Arimori K.

Drug Metab Dispos. 2005 May;33(5):644-8. Epub 2005 Jan 26.

PMID:
15673597
28.

Potent inhibition by star fruit of human cytochrome P450 3A (CYP3A) activity.

Hidaka M, Fujita K, Ogikubo T, Yamasaki K, Iwakiri T, Okumura M, Kodama H, Arimori K.

Drug Metab Dispos. 2004 Jun;32(6):581-3.

PMID:
15155547
29.

Inhibitory effects of citrus fruits on cytochrome P450 3A (CYP3A) activity in humans.

Fujita K, Hidaka M, Takamura N, Yamasaki K, Iwakiri T, Okumura M, Kodama H, Yamaguchi M, Ikenoue T, Arimori K.

Biol Pharm Bull. 2003 Sep;26(9):1371-3.

30.

Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats.

Arimori K, Kuroki N, Hidaka M, Iwakiri T, Yamsaki K, Okumura M, Ono H, Takamura N, Kikuchi M, Nakano M.

Pharm Res. 2003 Jun;20(6):910-7.

PMID:
12817897
31.

Hypoglycemic effect of surfactant-coated insulin solubilized in a novel solid-in-oil-in-water (S/O/W) emulsion.

Toorisaka E, Ono H, Arimori K, Kamiya N, Goto M.

Int J Pharm. 2003 Feb 18;252(1-2):271-4.

PMID:
12550804
32.

Prediction of plasma concentration-time curve of orally administered theophylline based on a scintigraphic monitoring of gastrointestinal transit in human volunteers.

Haruta S, Kawai K, Nishii R, Jinnouchi S, Ogawara Ki, Higaki K, Tamura S, Arimori K, Kimura T.

Int J Pharm. 2002 Feb 21;233(1-2):179-90.

PMID:
11897422
33.

Role of CYP3A4 and CYP2C19 in the stereoselective metabolism of lansoprazole by human liver microsomes.

Katsuki H, Hamada A, Nakamura C, Arimori K, Nakano M.

Eur J Clin Pharmacol. 2001 Dec;57(10):709-15.

PMID:
11829200
34.

Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea.

Ikegami T, Ha L, Arimori K, Latham P, Kobayashi K, Ceryak S, Matsuzaki Y, Bouscarel B.

Cancer Res. 2002 Jan 1;62(1):179-87.

35.

Excretion into gastrointestinal tract of irinotecan lactone and carboxylate forms and their pharmacodynamics in rodents.

Arimori K, Kuroki N, Kumamoto A, Tanoue N, Nakano M, Kumazawa E, Tohgo A, Kikuchi M.

Pharm Res. 2001 Jun;18(6):814-22.

PMID:
11474786
36.

High-performance liquid chromatographic assay for the simultaneous determination of lansoprazole enantiomers and metabolites in human liver microsomes.

Katsuki H, Hamada A, Nakamura C, Arimori K, Nakano M.

J Chromatogr B Biomed Sci Appl. 2001 Jun 5;757(1):127-33.

PMID:
11419737
38.

Evaluation of absorption kinetics of orally administered theophylline in rats based on gastrointestinal transit monitoring by gamma scintigraphy.

Haruta S, Kawai K, Jinnouchi S, Ogawara KI, Higaki K, Tamura S, Arimori K, Kimura T.

J Pharm Sci. 2001 Apr;90(4):464-73.

PMID:
11170036
39.

Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins.

Shiraki N, Hamada A, Yasuda K, Fujii J, Arimori K, Nakano M.

Biol Pharm Bull. 2000 Dec;23(12):1528-31.

PMID:
11145192
40.

Adrenomedullin increases phosphatidylcholine secretion in rat type II pneumocytes.

Okumura M, Kai H, Arimori K, Iwakiri T, Hidaka M, Shiramoto S, Isohama Y, Miyata T.

Eur J Pharmacol. 2000 Sep 8;403(3):189-94.

PMID:
10973618
41.

Effect of sex on serum protein binding characteristics of phenytoin in pediatric patients with epilepsy.

Kodama H, Kodama Y, Itokazu N, Arimori K, Kanemaru R, Sugimoto T, Fujimura A.

Am J Health Syst Pharm. 2000 Jun 15;57(12):1144-7. No abstract available.

PMID:
10911514
42.

Effect of clarithromycin and other macrolides on the sulfoxidation and 5-hydroxylation of lansoprazole in dogs.

Masa K, Arimori K, Nakayama T, Miyamoto S, Fujii J, Nakano M.

Biol Pharm Bull. 1999 May;22(5):504-9.

PMID:
10375172
43.
44.

Pharmacokinetic differences between lansoprazole enantiomers in rats.

Arimori K, Yasuda K, Katsuki H, Nakano M.

J Pharm Pharmacol. 1998 Nov;50(11):1241-5.

PMID:
9877309
45.

Characteristic difference in gastrointestinal excretion of clarithromycin and roxithromycin.

Arimori K, Miyamoto S, Fukuda K, Nakamura C, Nakano M.

Biopharm Drug Dispos. 1998 Oct;19(7):433-8.

PMID:
9818709
46.

Drug exsorption from blood into the gastrointestinal tract.

Arimori K, Nakano M.

Pharm Res. 1998 Mar;15(3):371-6. Review.

PMID:
9563065
47.

Protective effects of betamipron on renal toxicity during repeated cisplatin administration in rats and protective mechanism.

Tokunaga J, Kobayashi M, Kitagawa A, Nakamura C, Arimori K, Nakano M.

Ren Fail. 1998 Jan;20(1):27-38.

PMID:
9509558
48.
49.

Inhibition of nifedipine metabolism in dogs by erythromycin: difference between the gut wall and the liver.

Tsuruta S, Nakamura K, Arimori K, Nakano M.

J Pharm Pharmacol. 1997 Dec;49(12):1205-10.

PMID:
9466344
50.

p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents.

Thottassery JV, Zambetti GP, Arimori K, Schuetz EG, Schuetz JD.

Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):11037-42.

Supplemental Content

Loading ...
Support Center